New stroke drug HRS-7450 enters Mid-Stage trial
NCT ID NCT07233070
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This study tests an investigational drug called HRS-7450 in 208 people who have had an acute ischemic stroke within the past 4.5 to 24 hours. Participants receive either a low, intermediate, or high dose of the drug or a placebo. The goal is to see if the drug helps improve recovery, measured by disability scores at 90 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-7450 injection
- What this could lead to
- If successful, this could point toward a new treatment to improve recovery after a stroke by reducing brain damage.
- What could go wrong
- This is an early Phase 2 trial with only 208 participants, so results may not confirm benefit. The drug may not work better than placebo or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Linyi People's Hospital
Linyi, Shandong, 276002, China
-
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510062, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict stroke recovery?
- Can a drug boost brain recovery after stroke?
- Can a blood Clot's inflammation predict stroke recovery?
- Can a new infusion drug boost stroke recovery?
- Can removing clots from tiny brain arteries boost stroke recovery?
- Could vague stroke symptoms delay lifesaving treatment?